In this paper we discuss the possibility of using Hair Cortisol in Clinical Practice to monitor HPA status in patents at risk of developing the Metabolic Syndrome, and also its possible use to assess effectiveness of the effectiveness of treatment in patients with the Metabolic Syndrome.